Prostate Cancer Clinical Trials in Seattle, Washington

17 studies are recruiting for prostate cancer in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Seattle, Washington
    Locations
    346 in total
    Run by
    AstraZeneca

    See if you can join NCT06952803 on ClinicalTrials.gov

  2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  3. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    VA Puget Sound Health Care System ( Site 0054), Seattle, Washington
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  4. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  5. PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

    PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic e…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Washington Medical Center, Seattle, Washington
    Locations
    3 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT04995198 on ClinicalTrials.gov

  6. The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

    The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral d…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Washington, Seattle, Washington
    Locations
    4 in total
    Run by
    Yale University

    See if you can join NCT06111781 on ClinicalTrials.gov

  7. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

    The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    Swedish Medical Center, Seattle, Washington
    Locations
    95 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06855277 on ClinicalTrials.gov

  8. Precision-Based Genomics in Prostate Cancer

    Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene m…

    Stage
    Not phased
    Ages
    18 to 120
    Site
    University of Washington, Seattle, Washington
    Locations
    11 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04706663 on ClinicalTrials.gov

  9. Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

    This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study i…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Washington Medical Center, Seattle, Washington
    Locations
    14 in total
    Run by
    Monte Rosa Therapeutics, Inc

    See if you can join NCT07745361 on ClinicalTrials.gov

  10. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    57 in total
    Run by
    Amgen

    See if you can join NCT04221542 on ClinicalTrials.gov

  11. Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

    The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (A…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    9 in total
    Run by
    University of British Columbia

    See if you can join NCT04812366 on ClinicalTrials.gov

  12. Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

    The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    9 in total
    Run by
    Amgen

    See if you can join NCT06613100 on ClinicalTrials.gov

  13. Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

    The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance. The name of the study intervention involved in th…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
    Locations
    4 in total
    Run by
    Fred Hutchinson Cancer Center

    See if you can join NCT05918263 on ClinicalTrials.gov

  14. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    Fred Hutchinson Cancer Research Center, Seattle, Washington
    Locations
    81 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

  15. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    University of Washington Medical Center, Seattle, Washington
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  16. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  17. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fred Hutchinson Cancer Center, Seattle, Washington
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.